Altamira Therapeutics Ltd. (NASDAQ: CYTO) experienced a positive trend in its stock during the latest trading session, rising by 8.57% and concluding at $2.28. This increase was primarily influenced by a significant move related to a patent application made by Altamira.
In an announcement, Altamira (CYTO) revealed that it recently submitted a second provisional patent application to the United States Patent and Trade Office (USPTO). The purpose of this application is to establish comprehensive protection for the use of nanoparticles, specifically those developed through Altamira’s OligoPhore platform, and a unique siRNA sequence called polyKRASmut, in the treatment of various KRAS mutations in human cancers. These nanoparticles are identified as AM-401.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The supporting in vitro data in the second provisional application affirms the effectiveness of polyKRASmut siRNA in suppressing a wide range of KRAS mutations in cancer cell lines. It’s worth noting that, while polyKRASmut was tested against a limited number of mutations, there is potential for it to target other mutations that haven’t been examined yet.
Altamira highlighted recent data confirming polyKRASmut siRNA’s ability to target several KRAS mutations associated with severe forms of cancer. By combining this siRNA with the OligoPhore platform, Altamira can precisely deliver the treatment to the tumor, effectively addressing multiple KRAS mutations with a single compound.
This approach not only targets different KRAS mutations in cancer but also addresses resistance mechanisms developed by tumors, making them less responsive to traditional KRAS-directed therapies. Additionally, Altamira anticipates that AM-401 will be better tolerated than small molecule inhibitors since it specifically targets the affected organ without impacting healthy tissues.
The company anticipates that the second provisional patent application will enhance its intellectual property related to the AM-401 program, which aims to develop a treatment for cancers driven by KRAS mutations. Altamira plans to submit an Investigational New Drug (IND) application to the FDA in 2025 and is open to partnering the program following an IND approval or after completing a phase 1 clinical trial.
